Evolus, Inc. reaffirmed revenue guidance for full year 2022. For the period, based on its year-to-date performance and confidence in a resilient and fundamentally strong aesthetic neurotoxin market, the company continues to believe it can achieve the upper end of its full-year sales guidance range of $143 million to $150 million. This assumes a minimal contribution from international markets.